POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES
Domain expertise, global resource, long-term capital
PORTFOLIO NEWS
September 14, 2021Shanghai, China, Sep. 14, 2021 – Alebund Pharmaceuticals (“Alebund” or the “Company”), a...September 8, 2021SAN DIEGO, CA, September 8, 2021 – ADARx Pharmaceuticals, Inc., a biotechnology company...August 18, 2021HONG KONG, Aug. 17, 2021 /PRNewswire/ -- Shanghai MediTrust Health Technology Co., Ltd. ...August 9, 2021– Seagen Licenses Disitamab Vedotin, a Novel HER2-targeted Antibody-Drug Conjugate (ADC) from...August 5, 2021HONG KONG, Aug 5, 2021 - (ACN Newswire) - - Following the completion of series A round...NANJING, China, Aug. 3, 2021 /PRNewswire/ -- Pulnovo Medical, a pioneer medical device company,...INDIANAPOLIS, IN, and SAN DIEGO, CA, July 29, 2021 – Loxo Oncology at Lilly, a research and...Exclusive Global Development and Commercialization Rights for Recombinant Human Collagen-Based...More Posts
Company
Shanghai
Room 2909-14, 168 Hubin Road, Huangpu District, Shanghai, China.
Hong Kong
Room 606-7, St. George's Building, 2 Ice House Street, Central, Hong Kong
US
2730 Sand Hill Road, Suite 130, Menlo Park, CA
copyright © 2018 Lilly Asia Ventures all rights reserved.
沪公网安备 31010102005458号All Posts
×
LillyAsiaVentures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
https://user-assets.sxlcdn.com/images/315509/FnksTvTDur7jpExbqYminmtjWgoM.png?imageMogr2/strip/auto-orient/thumbnail/1200x630>/format/png